Navigation Links
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Date:6/6/2009

the FDA may not agree with Orexigen's interpretation of efficacy and safety results; earlier clinical trials may not be predictive of future results; Contrave or Empatic may not receive regulatory approval on a timely basis or at all, and the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave or Empatic to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave or Empatic, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
2. Orexigen(R) Therapeutics to Present at Upcoming Meetings
3. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
4. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
5. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
6. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
7. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... http://www.thirdbiotech.com ), a biotechnology incubator and life ... the ThirdBiotech Research,Group including a drug discovery ... of collaborative activities between researchers,and industry for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070911/LATU119LOGO ), "Over ...
... 25 The U.S. Food and Drug,Administration ... Drugs,voted to recommend the approval of tolvaptan, ... treatment,for patients with hyponatremia., "Otsuka is ... the,potential approval of tolvaptan, an investigational selective,V2-vasopressin ...
... is,strengthening its customer-focused biomarker services portfolio to,pharmaceutical, ... Xie will lead those efforts as Battelle,s ... a suite of biomarker services, including biomarker,discovery, ... clients,better define molecular mechanisms of diseases, toxicity, ...
Cached Biology Technology:ThirdBiotech Launches Research Institute to Promote Formation and Growth of Arizona-Based Biotech Companies 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2Battelle Selects Xie to Develop Biomarker Services 2
(Date:4/18/2014)... PROVIDENCE, R.I. [Brown University] Asteroid and comet impacts ... animals on regional or even global scales. But new ... preserve the signatures of ancient life at the time ... Brown geologist Pete Schultz has found fragments of leaves ... a several ancient impacts in Argentina. The material could ...
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... April 17, 2014The development of stem cell therapies to ... to characterize stem cell populations based on cell surface ... a new marker that is highly expressed in a ... blood, which they describe in an article in ... Ann Liebert, Inc., publishers. The article is available free ...
Breaking Biology News(10 mins):Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Multitarget TB drug could treat other diseases, evade resistance 2
... their native language of 1 and 0 absolutes but struggle ... While scientists are making slow, incremental progress in their quest ... body language, a more straightforward method of communication may help ... of researchers led by Charlie Kemp, director of the Center ...
... the equatorial Pacific long before Europeans arrived in the ... the way from modern-day Chile to western Mexico, according ... of Materials Science and Engineering. Details of ... years ago were reconstructed largely through the efforts of ...
... is a conspicuous and exaggerated display shaped by sexual ... attraction. At the level of the individual, song is ... Laiolo and colleagues at the Spanish Council of Research ... in north-eastern Spain and found an association between individual ...
Cached Biology News:Robot fetches objects with just a point and a click 2Robot fetches objects with just a point and a click 3Robot fetches objects with just a point and a click 4Floating a big idea: MIT demos ancient use of rafts to transport goods 2Floating a big idea: MIT demos ancient use of rafts to transport goods 3Floating a big idea: MIT demos ancient use of rafts to transport goods 4
... The University of New South Wales, Sydney, Australia ... Australia This is the Fourth Edition of this ... is a large format version (330 x ... 3rd edition. This product number includes the ...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
... The Jouan RC10 series of vacuum concentrators/centrifugal ... protection features allied to rapid and safe ... can be combined with oil-free or high ... and a wide selection of rotors (eliminating ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: